>
-Berry Declares Quarterly Dividend-Resumen: Precisely refuerza su oferta de Location Intelligence con la adquisición de Transerve-Curative Insurance Company’s Financial Strength Affirmed with A- (Excellent) Rating from AM Best and Infusion of $100 Million Demonstrates Curative’s Long-Term Commitment to Its Innovative Health Plan-Riveron Study Reveals Optimistic Outlook for Corporate Development in 2023-Stewart Information Services Corporation Announces Fourth Quarter 2022 Earnings Conference Call-Lake Shore Bancorp, Inc. Announces Full Year 2022 and Fourth Quarter Financial Results-Allied Announces Fourth-Quarter and Year-End Results-First Guaranty Reports Net Income of $28.9 Million for the Year 2022 and Fourth Quarter 2022 Net Income of $5.1 Million; Earnings Per Common Share Increased to $2.48 for the Year 2022 Compared to $2.42 for the Year 2021-QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END EARNINGS-Fidus Investment Corporation Announces Deemed Distribution of $1.65 per Share and U.S. Federal Income Tax Treatment of 2022 Dividends-Global Insulated Gate Bipolar Transistor [IGBT] Market Size To Grow USD 10 Billion By 2030 | CAGR 9%-U.S. Physical Therapy, Inc. Schedules Fourth Quarter and Year Ended 2022 Earnings Release and Conference Call-CRCAM Alpes Provence : mise à disposition de l’Avis financier au 31 décembre 2022-CRCAM Alpes Provence : Avis financier au 31 décembre 2022-Global Silicone Polymer Market Size To Surpass $35.90 Billion By 2030 | CAGR 6.4%-Crédit Agricole Brie Picardie : Résultats financiers au 31 décembre 2022-Alchimie Has Successfully Completed the First Phase of Its Transition and Announces 2022 Sales of €22 Million and the Achievement of Operational Profitability-Global Wireless Sensors Market Size To Grow USD 149 Billion By 2030 | CAGR of 19%-Global Radar Sensor Market Size To Grow USD 43.5 Billion By 2030 | CAGR 18.6%-Global Digital TV SoC Market Is Expected to Reach $28.2 Billion by 2031: Says AMR

Amplitude Surgical – First Quarter 2022-23: Consolidated Sales of €19.4 Million, +11.3% at Constant Exchange Rates

VALENCE, France–()–Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME equity savings plans) (Paris:AMPLI), a leading French player on the surgical technology market for lower-limb orthopedics, announces its sales for the first quarter of its 2022-23 financial year.

Olivier Jallabert, Amplitude Surgical’s CEO, said: “In the first quarter of our 2022-23 financial year, Amplitude Surgical recorded an increase in Group sales before application of IFRS 5 of 14.1%, benefiting from operating room availability returning to almost normal levels, which wasn’t the case in the first quarter of last year. Knee and hip activities generated growth of 11.3% at constant exchange rates. Novastep, meanwhile, continued its expansion and accounted for approximately 18.8% of Group sales before application of IFRS 5, with growth of almost 29% over the period”.

Q1 2022-23 sales

30/09/2022

30/09/2021

Change at current

exchange rates

Change at constant

exchange rates

In thousands of euros – IFRS

Knee and hip activity

19,406

17,037

13.9%

11.3%

Consolidated sales after application

of IFRS 5

19,406

17,037

13.9%

11.3%

Foot and ankle activity (Novastep)

4,480

3,151

42.2%

28.8%

Sales before application of IFRS 5

23,886

20,188

18.3%

14.1%

For its consolidated annual accounts to June 30, 2022, the Group applied IFRS 5 by classifying foot and ankle activities as “Non-current assets held for sale”. The Group’s consolidated sales for the first quarter of 2022-23 thus correspond solely to knee and hip activities. To provide a global view of the Group’s activities, sales before application of IFRS 5 and including foot and ankle activities are indicated in the table above.

Over the first quarter of its 2022-23 financial year (July-September 2022), Amplitude Surgical recorded sales before application of IFRS 5 of €23.9 million, up 18.3% in actual terms and 14.1% at constant exchange rates.

  • Knee and hip activity generated sales of €19.4 million, up 13.9% in actual terms and 11.3% at constant exchange rates. Activity in France increased by 12.2%, while international distributors generated growth of 15.3% and the Group’s international subsidiaries saw activity increase by 18.1% in actual terms and 7.9% at constant exchange rates. The first quarter of the previous year (2021-22) saw lower operating room availability and the postponement of surgical procedures, while this year operating room availability was virtually normal last quarter.

Knee and hip activity sales represent the Group’s consolidated sales after application of IFRS 5.

  • Novastep, innovative solutions for foot and ankle surgery, generated further strong growth in the first quarter, with sales totaling €4.5 million (+28.8% at constant exchange rates), driven by activity in both France and the United States. Novastep’s activity thus accounted for 18.8% of total Group sales before application of IFRS 5.

Next financial press release:

H1 2022-23 sales, on Thursday February 23, 2023, after market.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2022, Amplitude Surgical had a workforce of 460 employees and recorded sales of nearly 104.8 million euros (including foot and ankle activity and before application of IFRS 5).

Leave a Comment